<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int Med Res</journal-id><journal-id journal-id-type="iso-abbrev">J. Int. Med. Res</journal-id><journal-id journal-id-type="publisher-id">IMR</journal-id><journal-id journal-id-type="hwp">spimr</journal-id><journal-title-group><journal-title>The Journal of International Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0300-0605</issn><issn pub-type="epub">1473-2300</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7241267</article-id><article-id pub-id-type="doi">10.1177/0300060520925352</article-id><article-id pub-id-type="publisher-id">10.1177_0300060520925352</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pre-Clinical Research Report</subject></subj-group></article-categories><title-group><article-title>NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Yijun</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Zhen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Yuchuan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Shiying</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Bing</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4283-2625</contrib-id><name><surname>Zhan</surname><given-names>Lei</given-names></name><xref ref-type="corresp" rid="corresp1-0300060520925352"/></contrib><aff id="aff1-0300060520925352">Department of Gynecology and Obstetrics, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China</aff></contrib-group><author-notes><corresp id="corresp1-0300060520925352">Lei Zhan, Department of Gynecology and Obstetrics, Second Affiliated Hospital of Anhui Medical University, Furong Road No. 678, Hefei 230601, China. Email: <email>499329901@qq.com</email></corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2020</year></pub-date><volume>48</volume><issue>5</issue><elocation-id>0300060520925352</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec><title>Objective</title><p>NOD-like receptor family caspase recruitment domain family domain-containing 5 (NLRC5) is involved in the development of cancer. Our objective was to explore the role of NLRC5 in the progression of endometrial cancer (EC).</p></sec><sec><title>Methods</title><p>The roles of NLRC5 in migration and invasion of AN3CA EC cells were examined by cell wound-healing assay, Transwell migration, and invasion analysis. Overexpression of NLRC5 was achieved with NLRC5 plasmid, and knockdown of NLRC5 was achieved using small interfering (si)RNA-NLRC5 in AN3CA cells. The expression of NLRC5 was detected by immunohistochemical, western blot, and quantitative real-time PCR. LY294002 was used to inhibit the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway.</p></sec><sec><title>Results</title><p>NLRC5 was downregulated in EC tissue compared with normal endometrium. Overexpression of NLRC5 led to upregulation of cell migration and invasion in AN3CA cells and expression of matrix metallopeptidase (MMP)-9. Inhibition of NLRC5 restricted migration and invasion of AN3CA cells and expression of MMP9. Overexpression of NLRC5 promoted the activation of PI3K/AKT signaling pathway. Inhibiting PI3K/AKT signaling pathway by using LY294002 blocked the positive role of NLRC5 in migration and invasion of AN3CA cells and expression of MMP9.</p></sec><sec><title>Conclusions</title><p>These results demonstrate that NLRC5 promotes EC progression by activating the PI3K/AKT signaling pathway.</p></sec></abstract><kwd-group><kwd>NLRC5</kwd><kwd>endometrial cancer</kwd><kwd>migration</kwd><kwd>invasion</kwd><kwd>matrix metallopeptidase 9</kwd><kwd>phosphatidylinositol 3-kinase/AKT signaling pathway</kwd></kwd-group><funding-group><award-group id="award1-0300060520925352"><funding-source id="funding1-0300060520925352"><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001809</institution-id></institution-wrap></funding-source><award-id rid="funding1-0300060520925352">81802586</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts2</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-0300060520925352"><title>Introduction</title><p>Endometrial cancer (EC) is the most common gynecological malignancy in the developed world. The latest data estimate 61,880 new cases and 12,160 deaths in the United States in 2019. The mortality rate of EC is also increasing, with an average 1.9% change annually from 2007 to 2016.<sup><xref rid="bibr1-0300060520925352" ref-type="bibr">1</xref></sup> Risk factors in the development of EC include polycystic ovarian syndrome, tamoxifen therapy, anovulation, nulliparity, early age of menarche, later age of menopause onset, Lynch syndrome, and obesity.<sup><xref rid="bibr2-0300060520925352" ref-type="bibr">2</xref><xref rid="bibr3-0300060520925352" ref-type="bibr"/>&#x02013;<xref rid="bibr4-0300060520925352" ref-type="bibr">4</xref></sup> EC is usually treated primarily with surgery; total hysterectomy and removal of both tubes and ovaries represent the standard approach in treating EC. Although hysterectomy results in excellent cancer-related outcomes for patients with early-stage EC, the prognosis for patients with advanced stage disease and high-risk histological subtypes remains poor.<sup><xref rid="bibr5-0300060520925352" ref-type="bibr">5</xref></sup> Thus, elucidating the molecular mechanism of EC is crucial for the prevention and treatment of the disease.</p><p>Pattern recognition receptors (PRRs) are critical sensors in the recognition of pathogen-associated molecular patterns (PAMPs) and play dual roles in the regulation of tumor immunity.<sup><xref rid="bibr6-0300060520925352" ref-type="bibr">6</xref>,<xref rid="bibr7-0300060520925352" ref-type="bibr">7</xref></sup> For example, they can inhibit tumorigenesis by inducing immunogenic tumor cell death. They can also facilitate tumor growth through induction of the regulatory cell population and immunosuppressive cytokines.<sup><xref rid="bibr8-0300060520925352" ref-type="bibr">8</xref>,<xref rid="bibr9-0300060520925352" ref-type="bibr">9</xref></sup> The NOD-like receptor (NLR) family, caspase activation and recruitment domain (CARD) domain-containing 5 (NLRC5) is a newly found member of the NLR family, which contains more than 20 members in the mammalian genome.<sup><xref rid="bibr10-0300060520925352" ref-type="bibr">10</xref>,<xref rid="bibr11-0300060520925352" ref-type="bibr">11</xref></sup> Notably, recent studies have revealed controversial and alternating roles of NLRC5 in innate and adaptive immunity. For example, Cui et&#x000a0;al. found that NLRC5 inhibited nuclear factor-kappa B (NF-&#x003ba;B)-dependent responses by interacting with IKKa and IKKb and blocking their phosphorylation. NLRC5-specific short interfering (si)RNA knockdown enhanced the activation of NF-&#x003ba;B and the inflammatory response in RAW 264.7 cells.<sup><xref rid="bibr12-0300060520925352" ref-type="bibr">12</xref></sup> However, in LX-2 cells, Xu and co-workers found that overexpression of NLRC5 upregulated interleukin (IL)-6 and IL-1&#x003b2; secretion, and knockdown of NLRC5 by transfecting siRNA decreased IL-6 and IL-1&#x003b2; secretion.<sup><xref rid="bibr13-0300060520925352" ref-type="bibr">13</xref></sup> Accumulating studies present evidence that NLRC5 plays an important role in immune evasion of cancers, that NLRC5 is a target for immune evasion in cancer, and that a high level of NLRC5 is correlated with higher survival.<sup><xref rid="bibr14-0300060520925352" ref-type="bibr">14</xref>,<xref rid="bibr15-0300060520925352" ref-type="bibr">15</xref></sup> Furthermore, studies have shown that NLRC5 contributes to tumorigenesis by promoting cell proliferation, migration, and invasion in cancers related to a high inflammatory state.<sup><xref rid="bibr16-0300060520925352" ref-type="bibr">16</xref>,<xref rid="bibr17-0300060520925352" ref-type="bibr">17</xref></sup> For example, overexpression of NLRC5 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells (HCC) by activating the downstream Wnt/&#x003b2;-catenin signaling pathway.<sup><xref rid="bibr17-0300060520925352" ref-type="bibr">17</xref></sup> In line with this, NLRC5 has been shown to promote HCC tumor proliferation by promoting the AKT/VEGF-A signaling pathway.<sup><xref rid="bibr18-0300060520925352" ref-type="bibr">18</xref></sup> Han and co-workers, however, suggested that knockdown of NLRC5 restricted renal ischemia-reperfusion injury by activating the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway in vitro, indicating conflicting results about the role of NLRC5 in the PI3K/AKT signaling pathway.<sup><xref rid="bibr19-0300060520925352" ref-type="bibr">19</xref></sup> Nevertheless, the role and mechanism of NLRC5 in EC have been unclear until now. Furthermore, the exact role of NLRC5 in PI3K/AKT signaling pathway in EC needs to be validated.</p><p>The aim of our study was to uncover the molecular mechanism by which NLRC5 plays a role in EC. We used clinical tissue samples from patients with EC and an EC cell line, AN3CA, to demonstrate the roles of NLRC5 in progression of EC.</p></sec><sec sec-type="Materials|methods" id="sec2-0300060520925352"><title>Materials and methods</title><sec id="sec3-0300060520925352"><title>Human tissue samples</title><p>Endometrial tissue specimens from 20 patients with EC obtained at primary surgery and control endometrial tissue specimens from 20 patients undergoing hysterectomy for nonmalignant indications were collected and processed at the Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Anhui Medical University from January 2018 to January 2019. None of the patients had received chemotherapy or radiotherapy before surgery. All patients gave written informed content. The study was approved by the institutional review board of Anhui Medical University. The demographic characteristics of EC patients and of women in the control group are summarized in <xref rid="table1-0300060520925352" ref-type="table">Table 1</xref>. The two groups were matched for age. Samples were collected, quickly placed in liquid nitrogen, and stored at &#x02212;80&#x000b0;C for western blot assay (five EC tissue specimens and five control tissue specimens) and real-time quantitative reverse transcription-PCR (RT-qPCR) assay (five EC tissue specimens and five control tissue specimens). Ten EC tissue specimens and 10 control tissue specimens were prepared for formalin-fixed, paraffin-embedded tissue blocks for subsequent histopathological and immunohistochemical assay.</p><table-wrap id="table1-0300060520925352" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Demographic characteristics of patients with and without EC.</p></caption><alternatives><graphic xlink:href="10.1177_0300060520925352-table1"/><table frame="hsides" rules="groups"><thead valign="top"><tr><th rowspan="1" colspan="1">Variables</th><th rowspan="1" colspan="1">Patients without EC (n&#x02009;=&#x02009;20)</th><th rowspan="1" colspan="1">Patients with EC (n&#x02009;=&#x02009;20)</th><th rowspan="1" colspan="1">t</th><th rowspan="1" colspan="1">
<italic>p</italic>
</th></tr></thead><tbody valign="top"><tr><td rowspan="1" colspan="1">Age, years</td><td rowspan="1" colspan="1">51.70&#x02009;&#x000b1;&#x02009;3.74</td><td rowspan="1" colspan="1">53.95&#x02009;&#x000b1;&#x02009;4.15</td><td align="char" char="(" rowspan="1" colspan="1">1.801</td><td align="char" char="(" rowspan="1" colspan="1">0.080</td></tr><tr><td rowspan="1" colspan="1">Menopausal status</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Postmenopausal, no. (%)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">16 (80.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Premenopausal, no. (%)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">4 (20.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Histology</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Endometrioid</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">20 (100.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">FIGO stage (2009)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;I</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">8 (40.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;II</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">10 (50.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;III</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">2 (10.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Histological grade</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;G1</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">11 (55.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;G2</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">6 (30.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;G3</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">3 (15.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Myometrial invasion</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02264;50%</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">15 (75.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003e;50%</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">5 (25.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Lymphatic node metastasis</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">2 (10.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1">18 (90.0)</td><td align="char" char="(" rowspan="1" colspan="1"/><td align="char" char="(" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-0300060520925352"><p>EC, endometrial cancer; FIGO: Federation International of Gynecology and Obstetrics.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec4-0300060520925352"><title>Cell cultures</title><p>The human EC cell line AN3CA was obtained from the Shanghai Institute of Cell Biology of the Chinese Academy of Sciences (Shanghai, China). AN3CA cells were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA), and 1% penicillin/streptomycin (Invitrogen) in the incubator at 37&#x000b0;C under 5% CO<sub>2</sub>.</p></sec><sec id="sec5-0300060520925352"><title>Protein extraction and western blot analysis</title><p>Endometrial tissue specimens or AN3CA cells were lysed in protein extraction solution (Beyotime, Jiangsu, China). Lysates collected by centrifugation were applied on polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp., Billerica, MA, USA). After blocking nonspecific protein binding, nitrocellulose blots were incubated for 6 hours with primary antibodies diluted in primary antibody dilution buffer (Beyotime). The primary antibodies recognizing NLRC5 (ab105411, Abcam, Cambridge, MA, USA), MMP9 (#3852, Cell Signaling Technology, Danvers, MA), p-PI3K (AF3241, Affinity Biosciences, Cincinnati, OH, USA), PI3K (AF6241, Affinity Biosciences), p-AKT (AF0016, Affinity Biosciences), AKT (AF6261, Affinity Biosciences), and &#x003b2;-actin (GB12001, Servicebio, Wuhan, China) were used at 1:1,000, 1:1,000, 1:1,000, 1:1,000, 1:1,000, and 1:3,000, respectively. The membranes were then incubated in Tris-buffered saline-Tween (TBST; Boster Bio, Wuhan, China) containing 5% skim milk at 37&#x000b0;C for 4 hours, and with specific primary antibodies at 4&#x000b0;C overnight. The next day, the membranes were washed three times with TBS-Tween 20 (0.075%), followed by incubation with horseradish peroxidase-conjugated secondary antibodies (1:10,000) at 37&#x000b0;C for 1 hour. After washing three times with TBST, proteins were visualized using an ECL chemiluminescent kit (ECL-plus, Thermo Fisher Scientific, Waltham, MA, USA). All experiments were performed in triplicate and repeated at least three times.</p></sec><sec id="sec6-0300060520925352"><title>RNA isolation and RT-qPCR</title><p>Total RNA was extracted using TRIzol total RNA isolation reagents (Invitrogen), and first-strand cDNA was synthesized from total RNA using a Thermoscript RT-PCR synthesis kit (Fermentas, Burlington, ON, Canada) in accordance with the manufacturer&#x02019;s instructions. RT-qPCR analyses for mRNA of <italic>NLRC5</italic>, <italic>MMP9</italic>, and <italic>ACTB</italic> were carried out by using Thermoscript RT-qPCR kits in an ABI Prism Step-One Plus real time PCR System (Applied Biosystems, Foster City, CA, USA). The mRNA level of <italic>ACTB</italic> was used as an internal control. Relative expression levels were calculated based on the standard 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method. All experiments were performed in triplicate and repeated at least three times. The RT-qPCR primer sequences used are as follows: NLRC5-forward: 5&#x02032;-GTTCTTAGGGTTCCGTCAGCG-3&#x02032;, NLRC5-reverse: 5&#x02032;-CAGTCCTTCAGAGTGGCACAGAG-3&#x02032;; MMP9-forward: 5&#x02032;-ACGCACGACGTCTTCCAGTA-3&#x02032;, MMP9-reverse: 5&#x02032;-CCACCTGGTTCAACTCACTCC-3&#x02032;; ACTB-forward: 5&#x02032;-CACCCAGCACAATGAAGATCAAGAT-3&#x02032;, ACTB-reverse: 5&#x02032;-CCAGTTTTTAAATCCTGAGTCAAGC-3&#x02032;.</p></sec><sec id="sec7-0300060520925352"><title>Transient transfection of AN3CA cells of NLRC5 plasmid and siRNA-NLRC5</title><p>The full-length coding region (1,276 bp) of NLRC5 was amplified from human genomic DNA by reverse transcription (RT)-PCR using the following primers: forward: 5&#x02032;-CCGGAATTCCGGATGGCCAGGAAGCTGGA-3&#x02032; and reverse: 5&#x02032;-GGGATCCCGTCACCTGAGTGTCTTCCCA-3&#x02032;.</p><p>The PCR products were digested with EcoRI/BamHI and were inserted into the pEGFP-C2 empty vector (Clontech, Shanghai, China). The recombinant construct pEGFP-C2-NLRC5 was verified by direct DNA sequencing. Cell transfection was performed with Lipofectamine 2000 (Invitrogen) according to the manufacturer&#x02019;s instructions. Small interfering (si)RNA oligonucleotides against NLRC5 or scrambled sequences were designed and synthesized by the Gema Pharma Corporation (Shanghai, China) and contained the following sequences: siRNA-NLRC5-sense: AAGAACGAGAGACUCUGCCAACUGCdTdT, siRNA-NLRC5-antisense: GCAGUUGGCAGAGUCUCUCGUUCUUdTdT, scrambled-RNAi-sense: UUCUCCGAACGUGUCACGUTT, and scrambled-RNAi-antisense: ACGUGACACGUUCGGAGAATT.</p><p>The AN3CA cells were cultured in 6-well plates with antibiotics-free DMEM for 24 hours and then transfected with siRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer&#x02019;s protocol.</p></sec><sec id="sec8-0300060520925352"><title>Cell wound healing assay</title><p>A wound healing assay was used to assess cell migration. After the appropriate treatments, cells (1&#x02009;&#x000d7;&#x02009;10<sup>5</sup>) were trypsinized, seeded into a 6-well plate, and allowed to grow to 75% confluence in complete medium. Then, the cell layer was wounded using a sterile pipette tip, washed with PBS several times to remove cell debris, and incubated for 48 hours in serum-free medium. During incubation at 37&#x000b0;C, cells migrated into the wound surface, a process of in vitro healing. The wound healing in vitro was photographed by using an inverted fluorescence microscope and the rate of closure was assessed, as follows. Rate of wound healing&#x02009;=&#x02009;[(wound width at 0 hours &#x02013; wound width at 48 hours)/0-hour wound width]&#x02009;&#x000d7;&#x02009;100%.</p></sec><sec id="sec9-0300060520925352"><title>Cell Transwell migration and invasion analysis</title><p>A 24-well Transwell Boyden chamber (Corning Inc., Corning, NY, USA) with an 8.0-&#x003bc;m pore size polycarbonate membrane was used for the migration and invasion assay, according to the manufacturer&#x02019;s protocol. For the migration assay, after appropriate treatments, cells were trypsinized and seeded in the upper chamber at a density of 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/well in 100&#x02009;&#x003bc;L of serum-free medium. Then, 600&#x02009;&#x003bc;L of complete medium was added to the lower chamber as a chemoattractant. After incubation for 24 hours at 37&#x000b0;C, cells remaining at the upper surface of the membrane were removed with cotton swabs. The cells on the lower surface of the membrane represent the migrated cells. After fixation with 4% paraformaldehyde and staining with crystal violet solution, cells that passed through the filter were photographed by using an inverted fluorescence microscope. The cell invasion assay was carried out similarly, except that 100&#x02009;&#x003bc;L of 1:8 DMEM-diluted Matrigel (BD, Franklin Lakes, NJ, USA) was added to each well at 37&#x000b0;C for 6 hours before cells were seeded onto the membrane, followed by incubation for 48 hours.</p></sec><sec id="sec10-0300060520925352"><title>Treatment of AN3CA cells with PI3K/AKT inhibitor LY294002</title><p>The PI3K/AKT inhibitor LY294002 (Sigma Chemical Co., St. Louis, MO, USA) was dissolved in dimethyl sulfoxide (Sigma Chemical Co.). A previous study showed that 20&#x02009;&#x003bc;M LY294002 could inhibit the PI3K/AKT pathway in EC cell lines.<sup><xref rid="bibr20-0300060520925352" ref-type="bibr">20</xref></sup> Furthermore, 10, 20, 30, and 40&#x02009;&#x003bc;M LY294002 could inhibit survival of cancer cells significantly, including EC cell lines.<sup><xref rid="bibr21-0300060520925352" ref-type="bibr">21</xref></sup> Therefore, we used LY294002 at a concentration of 25&#x02009;&#x003bc;M to inhibit the PI3K/AKT pathway in AN3CA cells. The AN3CA cells were seeded overnight in culture dishes and transfected with NLRC5 plasmid 6 hours later; then, AN3CA cells were treated with LY294002 for 48 hours.</p></sec><sec id="sec11-0300060520925352"><title>Statistical analysis</title><p>All data were analyzed by the SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA) and presented as means&#x02009;&#x000b1;&#x02009;standard deviations. The statistical significance of differences was determined by Student&#x02019;s <italic>t</italic>-test for comparison between means or one-way analysis of variance (ANOVA). Data were regarded as statistically significant at *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 and **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></sec></sec><sec sec-type="results" id="sec12-0300060520925352"><title>Results</title><sec id="sec13-0300060520925352"><title>NLRC5 was downregulated in human EC endometrial tissues</title><p>An immunohistochemical assay was first performed to analyze the NLRC5 expression level in EC tumor and normal endometrium tissues. In <xref ref-type="fig" rid="fig1-0300060520925352">Figure 1A</xref>, NLRC5 expression in EC tumor tissues was significantly lower than the endometrium tissues of control patients (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). Consistently, western blot (<xref ref-type="fig" rid="fig1-0300060520925352">Figure 1B</xref>) and RT-qPCR (<xref ref-type="fig" rid="fig1-0300060520925352">Figure 1C</xref>) analysis showed that the level of NLRC5 in EC tumor tissues was significantly downregulated compared with that in control tissues (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). These results demonstrate that NLRC5 is involved in the progression of EC.</p><fig id="fig1-0300060520925352" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>NLRC5 was downregulated in human EC tissues. (A) The endometrial tissues of control patients and patients with EC were stained by immunohistochemistry with NLRC5 (100&#x000d7;). (B) The protein expression of NLRC5 in control endometrium tissues and EC tumor tissues; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs control patients. (C) The mRNA expression of <italic>NLRC5</italic> in control endometrium tissues and EC tumor tissues; **<italic>p</italic> &#x0003c;0.01 vs control patients. NLRC5, NOD-like receptor family caspase recruitment domain family domain-containing 5; EC, endometrial cancer.</p></caption><graphic xlink:href="10.1177_0300060520925352-fig1"/></fig></sec><sec id="sec14-0300060520925352"><title>Overexpression of NLRC5 enhanced cell migration and invasion of AN3CA cells</title><p>To investigate the role of NLRC5 in EC, NLRC5 plasmid was constructed, and transfection was performed to overexpress NLRC5 protein and mRNA in AN3CA cells (<xref ref-type="fig" rid="fig2-0300060520925352">Figure 2A and B</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). After transfection, wound healing and Transwell assays were used to assess cell migration and invasion. As shown in <xref ref-type="fig" rid="fig2-0300060520925352">Figure 2C and D</xref>, overexpression of NLRC5 enhanced migration and invasion of AN3CA cells (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). Furthermore, as shown in <xref ref-type="fig" rid="fig2-0300060520925352">Figure 2E and F</xref>, overexpression of NLRC5 enhanced expression of MMP9 in AN3CA cells (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><fig id="fig2-0300060520925352" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Overexpression of NLRC5 enhanced cell migration and invasion of AN3CA cells. (A, B) AN3CA cells were transfected with NLRC5 plasmid and NLRC5 protein and mRNA expression was measured in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group. (C) Wound healing assay indicated that migration of AN3CA cells was upregulated after transfection with NLRC5 plasmid; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group. (D) Transwell invasion assays showed that overexpression of NLRC5 increased the invasion rate in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group. (E, F) MMP9 protein and mRNA expression was measured in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group. NLRC5, NOD-like receptor family caspase recruitment domain family domain-containing 5; AN3CA, endometrial cancer cell line; MMP9, metallopeptidase 9.</p></caption><graphic xlink:href="10.1177_0300060520925352-fig2"/></fig></sec><sec id="sec15-0300060520925352"><title>Inhibition of NLRC5 repressed cell migration and invasion of AN3CA cells</title><p>To further investigate the role of NLRC5 in EC, NLRC5 siRNA was constructed, and transfection was performed to inhibit NLRC5 protein and mRNA in AN3CA cells (<xref ref-type="fig" rid="fig3-0300060520925352">Figure 3A and B</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). After transfection, wound healing and Transwell assays were used to detect cell migration and invasion. As shown in <xref ref-type="fig" rid="fig3-0300060520925352">Figure 3C and D</xref>, inhibition of NLRC5 repressed migration and invasion of AN3CA cells (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, respectively). Furthermore, as shown in <xref ref-type="fig" rid="fig3-0300060520925352">Figure 3E and F</xref>, inhibition of NLRC5 restricted the expression of MMP9 in AN3CA cells (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01).</p><fig id="fig3-0300060520925352" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Inhibition of NLRC5 repressed cell migration and invasion of AN3CA cells. (A, B) AN3CA cells were transfected with NLRC5-siRNA, NLRC5 protein and mRNA expression was measured in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. scrambled siRNA group. (C) Wound healing assay indicated that migration of AN3CA cells was downregulated after transfection with NLRC5-siRNA; *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 vs. scrambled siRNA group. (D) Transwell invasion assays showed that inhibition of NLRC5 repressed invasion rate in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. scrambled siRNA group. (E, F) MMP9 protein and mRNA expression was measured in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. scrambled siRNA group. NLRC5, NOD-like receptor family caspase recruitment domain family domain-containing 5; AN3CA, endometrial cancer cell line; NLRC-siRNA, NLRC5 short interfering RNA; MMP9, metallopeptidase 9.</p></caption><graphic xlink:href="10.1177_0300060520925352-fig3"/></fig></sec><sec id="sec16-0300060520925352"><title>NLRC5 promoted AN3CA cell migration and invasion by activating the PI3K/AKT signaling pathway</title><p>To investigate the molecular mechanism of NLRC5 in EC, we first found that overexpression of NLRC5 led to activation of the PI3K/AKT signaling pathway (<xref ref-type="fig" rid="fig4-0300060520925352">Figure 4A</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), and downregulation of NLRC5 inhibited the PI3K/AKT signaling pathway (<xref ref-type="fig" rid="fig4-0300060520925352">Figure 4B</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). Furthermore, the PI3K/AKT signaling pathway inhibitor LY294002 restricted the role of NLRC5 in the PI3K/AKT signaling pathway (<xref ref-type="fig" rid="fig4-0300060520925352">Figure 4C</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). In addition, LY294002 blocked cell migration and invasion in AN3CA cells overexpressing NLRC5 (<xref ref-type="fig" rid="fig4-0300060520925352">Figure 4D and E</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). Consistently, LY294002 inhibited the expression of MMP9 in AN3CA cells overexpressing NLRC5 (<xref ref-type="fig" rid="fig4-0300060520925352">Figure 4F and G</xref>, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01). These results demonstrate that NLRC5 promotes EC cell migration and invasion by activating the PI3K/AKT signaling pathway.</p><fig id="fig4-0300060520925352" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>NLRC5 promoted AN3CA cell migration and invasion by activating PI3K/AKT signaling pathway. (A) AN3CA cells were transfected with NLRC5 plasmid and phosphorylated (p)-PI3K and p-AKT protein expression was measured in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group. (B) AN3CA cells were transfected with NLRC5-siRNA and p-PI3K and p-AKT protein expression was measured in AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. scrambled siRNA group. (C) NLRC5 plasmid-transfected AN3CA cells were treated with 25 &#x000b5;M LY294002 for 48 hours. Protein expression of p-PI3K and p-AKT was assessed by western blot; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group, <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. NLRC5 plasmid group. (D) NLRC5 plasmid-transfected AN3CA cells were treated with 25 &#x000b5;M LY294002 for 48 hours. Wound healing assay indicated that migration of NLRC5 plasmid-transfected AN3CA cells was downregulated after treatment with 25 &#x000b5;M LY294002; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group, <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. NLRC5 plasmid group. (E) NLRC5 plasmid transfected AN3CA cells were treated with 25 &#x000b5;M LY294002 for 48 hours. Transwell invasion assays showed that inhibition of PI3K/AKT signaling pathway repressed the invasion rate in NLRC5 plasmid-transfected AN3CA cells; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group, <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. NLRC5 plasmid group. (F, G) Protein expression of MMP9 was assessed by western blot and RT-qPCR; **<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. vector group, <sup>##</sup><italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01 vs. NLRC5 plasmid group. NLRC5, NOD-like receptor family caspase recruitment domain family domain-containing 5; AN3CA, endometrial cancer cell line; NLRC-siRNA, NLRC5 short interfering RNA; MMP9, metallopeptidase 9; LY294002, inhibitor of PI3K/AKT signaling pathway.</p></caption><graphic xlink:href="10.1177_0300060520925352-fig4"/></fig></sec></sec><sec sec-type="discussion" id="sec17-0300060520925352"><title>Discussion</title><p>In the present study, we demonstrated that NLRC5 was downregulated in endometrium of EC patients. Overexpression of NLRC5 promoted migration and invasion of AN3CA cells, and downregulation of NLRC5 inhibited migration and invasion of AN3CA cells. Furthermore, we found that NLRC5 promotes migration and invasion of AN3CA cells by activating the PI3K/AKT signaling pathway.</p><p>PRRs are critical sensors in PAMP recognition, which provide the first line of defense against invading microbes in the innate immune response.<sup><xref rid="bibr22-0300060520925352" ref-type="bibr">22</xref>,<xref rid="bibr23-0300060520925352" ref-type="bibr">23</xref></sup> The NOD-like receptors are a recently discovered family of cytoplasmic PRRs. NLRs are evolutionarily conserved proteins that sponsor the induction of innate and adaptive immunity.<sup><xref rid="bibr24-0300060520925352" ref-type="bibr">24</xref>,<xref rid="bibr25-0300060520925352" ref-type="bibr">25</xref></sup> Recently, it has been shown that NLRs play roles in cancer and inflammation.<sup><xref rid="bibr9-0300060520925352" ref-type="bibr">9</xref>,<xref rid="bibr26-0300060520925352" ref-type="bibr">26</xref>,<xref rid="bibr27-0300060520925352" ref-type="bibr">27</xref></sup> NLRC5 is a novel member of the NLR family;<sup><xref rid="bibr28-0300060520925352" ref-type="bibr">28</xref></sup> it possesses three structural domains: the N-terminal atypical CARD, which is completely distinct from the other NLRs; the central NACHT domain, which contains the nucleotide binding domain; and 27 leucine-rich repeats at the C-terminal. NLRC5 has the longest leucine-rich repeat domain of all human NLR proteins and is the largest member of the NLR family, with a predicted size of more than 200 kDa.<sup><xref rid="bibr29-0300060520925352" ref-type="bibr">29</xref></sup> NLRC5 is a transcriptional coactivator of the major histocompatibility complex (MHC) class I antigen presentation pathway, suggesting a critical role of NLRC5 in the human adaptive immune system.<sup><xref rid="bibr30-0300060520925352" ref-type="bibr">30</xref></sup> Accumulating evidence confirms that NLRC5 has a close relationship with cancer. On the one hand, NLRC5 is downregulated and acts as a target for immune evasion in cancer, and high levels of NLRC5 are correlated with higher survival of cancer patients.<sup><xref rid="bibr31-0300060520925352" ref-type="bibr">31</xref></sup> On the other hand, novel studies have shown that NLRC5 is upregulated and implicated in tumorigenesis by promoting cell proliferation, migration, and invasion in high inflammatory and immune state&#x02013;related cancers.<sup><xref rid="bibr16-0300060520925352" ref-type="bibr">16</xref><xref rid="bibr17-0300060520925352" ref-type="bibr"/>&#x02013;<xref rid="bibr18-0300060520925352" ref-type="bibr">18</xref></sup> However, the role and mechanism of NLRC5 in EC is unclear. In our study, we found that NLRC5 was downregulated in endometrium of EC patients compared with that of patients without EC. Furthermore, overexpression of NLRC5 promoted migration and invasion of AN3CA cells and expression of MMP9. Downregulation of NLRC5 inhibited migration and invasion of AN3CA cells and expression of MMP9. These results are consistent with the role of NLRC5 in other cancers, including HCC and renal cancer.</p><p>Activation of the PI3K/AKT signaling pathway is considered a marker of cancer progression, including that in EC.<sup><xref rid="bibr32-0300060520925352" ref-type="bibr">32</xref>,<xref rid="bibr33-0300060520925352" ref-type="bibr">33</xref></sup> Previous studies have suggested a close relationship between NLRC5 and the PI3K/AKT signaling pathway. However, NLRC5 has been reported to both promote and inhibit PI3K/AKT signaling in different diseases.<sup><xref rid="bibr18-0300060520925352" ref-type="bibr">18</xref>,<xref rid="bibr19-0300060520925352" ref-type="bibr">19</xref></sup> Here, our data suggested that NLRC5 can promote migration and invasion of AN3CA cells by stimulating the PI3K/AKT signaling pathway. Furthermore, when the PI3K/AKT signaling pathway was inhibited by its specific inhibitor LY294002, the role of NLCR5 in migration and invasion of AN3CA cells was abolished.</p><p>The aim of this study was to investigate whether NLRC5 promoted cell migration and invasion of EC cells by targeting the PI3K/AKT signaling pathway in vitro. Further research should examine the mechanism of NLRC5 in the regulation of cell migration and invasion in other EC cell lines. Moreover, these effects should be investigated and confirmed in vivo. We found that NLRC5 was downregulated in EC but played a positive role in EC progression. We propose that DNA methylation at a CpG island in the NLRC5, copy number loss of the NLRC5 gene, or somatic mutations in NLRC5 may lead to NLRC5 downregulation in EC compared with normal tissue,<sup><xref rid="bibr31-0300060520925352" ref-type="bibr">31</xref></sup> although this hypothesis requires further validation.</p><p>In summary, we demonstrated that expression of NLRC5 was low in endometrial tissue of patients with EC. Overexpression of NLRC5 promoted migration and invasion of AN3CA cells and expression of MMP9, whereas downregulation of NLRC5 inhibited migration and invasion of AN3CA cells and expression of MMP9. The PI3K/AKT signaling pathway is involved the role of NLRC5 in migration and invasion. These findings indicate that NLRC5 might be a novel therapeutic target for the treatment of EC.</p></sec></body><back><sec id="sec20-0300060520925352"><title>Authors&#x02019; contributions</title><p>YJF and LZ wrote the manuscript, YCS and SYS performed the statistical analysis, and WB and LZ supervised all protocols. All authors read, provided feedback, and approved the final manuscript.</p></sec><sec id="sec18-0300060520925352"><title>Declaration of conflicting interest</title><p>The authors declare that there is no conflict of interest.</p></sec><sec id="sec19-0300060520925352"><title>Funding</title><p>This study was supported by the National Natural Science Foundation of China (No 81802586) and Natural Science Foundation of Colleges and Universities (No KJ2017A197).</p></sec><sec><title>ORCID iD</title><p>Lei Zhan <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-4283-2625">https://orcid.org/0000-0003-4283-2625</ext-link></p></sec><ref-list content-type="numbered"><title>References</title><ref id="bibr1-0300060520925352"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group>
<article-title>Cancer statistics, 2019.</article-title>
<source>CA Cancer J Clin</source>
<year>2019</year>; 
<volume>69</volume>: <fpage>7</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">30620402</pub-id></mixed-citation></ref><ref id="bibr2-0300060520925352"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Snyder</surname><given-names>CL</given-names></name><name><surname>Shaw</surname><given-names>TG</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Milestones of Lynch syndrome: 1895&#x02013;2015.</article-title>
<source>Nat Rev Cancer</source>
<year>2015</year>; 
<volume>15</volume>: <fpage>181</fpage>&#x02013;<lpage>194</lpage>.<pub-id pub-id-type="pmid">25673086</pub-id></mixed-citation></ref><ref id="bibr3-0300060520925352"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boretto</surname><given-names>M</given-names></name><name><surname>Maenhoudt</surname><given-names>N</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.</article-title>
<source>Nat Cell Biol</source>
<year>2019</year>; 
<volume>21</volume>: <fpage>1041</fpage>&#x02013;<lpage>1051</lpage>.<pub-id pub-id-type="pmid">31371824</pub-id></mixed-citation></ref><ref id="bibr4-0300060520925352"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onstad</surname><given-names>MA</given-names></name><name><surname>Schmandt</surname><given-names>RE</given-names></name><name><surname>Lu</surname><given-names>KH.</given-names></name></person-group>
<article-title>Addressing the role of obesity in endometrial cancer risk, prevention, and treatment.</article-title>
<source>J Clin Oncol</source>
<year>2016</year>; 
<volume>34</volume>: <fpage>4225</fpage>&#x02013;<lpage>4230</lpage>.<pub-id pub-id-type="pmid">27903150</pub-id></mixed-citation></ref><ref id="bibr5-0300060520925352"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Suh</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Major clinical research advances in gynecologic cancer in 2018.</article-title>
<source>J Gynecol Oncol</source>
<year>2019</year>; 
<volume>30</volume>: <fpage>e18</fpage>.<pub-id pub-id-type="pmid">30806045</pub-id></mixed-citation></ref><ref id="bibr6-0300060520925352"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kaisho</surname><given-names>T.</given-names></name></person-group>
<article-title>Toll-like receptors: critical proteins linking innate and acquired immunity.</article-title>
<source>Nat Immunol</source>
<year>2001</year>; 
<volume>2</volume>: <fpage>675</fpage>&#x02013;<lpage>680</lpage>.<pub-id pub-id-type="pmid">11477402</pub-id></mixed-citation></ref><ref id="bibr7-0300060520925352"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Donovan</surname><given-names>DH</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Mele</surname><given-names>DA.</given-names></name></person-group>
<article-title>The next generation of pattern recognition receptor agonists: improving response rates in cancer immunotherapy</article-title>. <source>Curr Med Chem</source>
<year>2019</year>; 26: 1&#x02013;19. DOI: 10.2174/0929867326666190620103105.</mixed-citation></ref><ref id="bibr8-0300060520925352"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradere</surname><given-names>JP</given-names></name><name><surname>Dapito</surname><given-names>DH</given-names></name><name><surname>Schwabe</surname><given-names>RF.</given-names></name></person-group>
<article-title>The Yin and Yang of Toll-like receptors in cancer.</article-title>
<source>Oncogene</source>
<year>2014</year>; 
<volume>33</volume>: <fpage>3485</fpage>&#x02013;<lpage>3495</lpage>.<pub-id pub-id-type="pmid">23934186</pub-id></mixed-citation></ref><ref id="bibr9-0300060520925352"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>M</given-names></name><name><surname>Yeretssian</surname><given-names>G.</given-names></name></person-group>
<article-title>NOD-Like receptors: master regulators of inflammation and cancer</article-title>. <source>Front Immunol</source>
<year>2014</year>; 
<volume>5</volume>: <fpage>327</fpage>.<pub-id pub-id-type="pmid">25071785</pub-id></mixed-citation></ref><ref id="bibr10-0300060520925352"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>P</given-names></name><name><surname>Jian</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARgamma.</article-title>
<source>Nat Commun</source>
<year>2019</year>; 
<volume>10</volume>: <fpage>2882</fpage>.<pub-id pub-id-type="pmid">31253783</pub-id></mixed-citation></ref><ref id="bibr11-0300060520925352"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group>
<article-title>NLRC5: a paradigm for NLRs in immunological and inflammatory reaction.</article-title>
<source>Cancer Lett</source>
<year>2019</year>; 
<volume>451</volume>: <fpage>92</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="pmid">30867141</pub-id></mixed-citation></ref><ref id="bibr12-0300060520925352"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways.</article-title>
<source>Cell</source>
<year>2010</year>; 
<volume>141</volume>: <fpage>483</fpage>&#x02013;<lpage>496</lpage>.<pub-id pub-id-type="pmid">20434986</pub-id></mixed-citation></ref><ref id="bibr13-0300060520925352"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Ni</surname><given-names>MM</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5 mediates IL-6 and IL-1beta secretion in LX-2 cells and modulated by the NF-kappaB/Smad3 pathway</article-title>. <source>Inflammation</source>
<year>2015</year>; 
<volume>38</volume>: <fpage>1794</fpage>&#x02013;<lpage>1804</lpage>.<pub-id pub-id-type="pmid">25820389</pub-id></mixed-citation></ref><ref id="bibr14-0300060520925352"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>M</given-names></name><name><surname>Janikovits</surname><given-names>J</given-names></name><name><surname>von Knebel</surname><given-names>DM</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Complex pattern of immune evasion in MSI colorectal cancer.</article-title>
<source>Oncoimmunology</source>
<year>2018</year>; 
<volume>7</volume>: <fpage>e1445453</fpage>.<pub-id pub-id-type="pmid">29900056</pub-id></mixed-citation></ref><ref id="bibr15-0300060520925352"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshihama</surname><given-names>S</given-names></name><name><surname>Vijayan</surname><given-names>S</given-names></name><name><surname>Sidiq</surname><given-names>T</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5/CITA: a key player in cancer immune surveillance.</article-title>
<source>Trends Cancer</source>
<year>2017</year>; 
<volume>3</volume>: <fpage>28</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">28718425</pub-id></mixed-citation></ref><ref id="bibr16-0300060520925352"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Ding</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/beta-catenin signalling pathway in clear cell renal cell carcinoma.</article-title>
<source>Cancer Lett</source>
<year>2019</year>; 
<volume>444</volume>: <fpage>9</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">30543814</pub-id></mixed-citation></ref><ref id="bibr17-0300060520925352"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>YY</given-names></name><name><surname>He</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/beta-catenin signaling pathway.</article-title>
<source>Cancer Lett</source>
<year>2016</year>; 
<volume>376</volume>: <fpage>10</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">26975630</pub-id></mixed-citation></ref><ref id="bibr18-0300060520925352"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>YH</given-names></name><name><surname>Li</surname><given-names>MF</given-names></name><name><surname>Zhang</surname><given-names>XY</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma.</article-title>
<source>Toxicology</source>
<year>2016</year>; 
<volume>359&#x02013;360</volume>: <fpage>47</fpage>&#x02013;<lpage>57</lpage>.</mixed-citation></ref><ref id="bibr19-0300060520925352"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>CG</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Knockdown of NLRC5 attenuates renal I/R injury in vitro through the activation of PI3K/Akt signaling pathway.</article-title>
<source>Biomed Pharmacother</source>
<year>2018</year>; 
<volume>103</volume>: <fpage>222</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">29655162</pub-id></mixed-citation></ref><ref id="bibr20-0300060520925352"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>E</given-names></name><name><surname>Sorolla</surname><given-names>A.</given-names></name></person-group>
<article-title>Sensitizing endometrial cancer to ionizing radiation by multi-tyrosine kinase inhibition</article-title>. <source>J Gynecol Oncol</source>
<year>2019</year>; 
<volume>31</volume>: <fpage>e29</fpage>. DOI: 10.3802/jgo.2020.31.e29.<pub-id pub-id-type="pmid">31912683</pub-id></mixed-citation></ref><ref id="bibr21-0300060520925352"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HR</given-names></name><name><surname>Shagisultanova</surname><given-names>EI</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin.</article-title>
<source>Cancer Res</source>
<year>2004</year>; 
<volume>64</volume>: <fpage>4760</fpage>&#x02013;<lpage>4767</lpage>.<pub-id pub-id-type="pmid">15256444</pub-id></mixed-citation></ref><ref id="bibr22-0300060520925352"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>DAMP-sensing receptors in sterile inflammation and inflammatory diseases</article-title>. <source>Nat Rev Immunol</source>
<year>2019</year>; 
<volume>20</volume>: <fpage>95</fpage>&#x02013;<lpage>112</lpage>. DOI: 10.1038/s41577-019-0215-7.<pub-id pub-id-type="pmid">31558839</pub-id></mixed-citation></ref><ref id="bibr23-0300060520925352"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X.</given-names></name></person-group>
<article-title>Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.</article-title>
<source>Nat Rev Immunol</source>
<year>2016</year>; 
<volume>16</volume>: <fpage>35</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">26711677</pub-id></mixed-citation></ref><ref id="bibr24-0300060520925352"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Reconstitution and structure of a plant NLR resistosome conferring immunity</article-title>. <source>Science</source>
<year>2019</year>; 
<volume>364</volume>: pii: eaav5870.</mixed-citation></ref><ref id="bibr25-0300060520925352"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Dodds</surname><given-names>PN</given-names></name><name><surname>Bernoux</surname><given-names>M.</given-names></name></person-group>
<article-title>What do we know about NOD-like receptors in plant immunity?</article-title>
<source>Annu Rev Phytopathol</source>
<year>2017</year>; 
<volume>55</volume>: <fpage>205</fpage>&#x02013;<lpage>229</lpage>.<pub-id pub-id-type="pmid">28637398</pub-id></mixed-citation></ref><ref id="bibr26-0300060520925352"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udden</surname><given-names>SN</given-names></name><name><surname>Kwak</surname><given-names>YT</given-names></name><name><surname>Godfrey</surname><given-names>V</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRP12 suppresses hepatocellular carcinoma via downregulation of cJun N-terminal kinase activation in the hepatocyte</article-title>. <source>Elife</source>
<year>2019</year>; 
<volume>8</volume>: pii: e40396.</mixed-citation></ref><ref id="bibr27-0300060520925352"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>WJ</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Molecular mechanism for NLRP6 inflammasome assembly and activation.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2019</year>; 
<volume>116</volume>: <fpage>2052</fpage>&#x02013;<lpage>2057</lpage>.<pub-id pub-id-type="pmid">30674671</pub-id></mixed-citation></ref><ref id="bibr28-0300060520925352"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>TB</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Biswas</surname><given-names>A</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2010</year>; 
<volume>107</volume>: <fpage>13794</fpage>&#x02013;<lpage>13799</lpage>.<pub-id pub-id-type="pmid">20639463</pub-id></mixed-citation></ref><ref id="bibr29-0300060520925352"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutte</surname><given-names>PG</given-names></name><name><surname>Jurt</surname><given-names>S</given-names></name><name><surname>Grutter</surname><given-names>MG</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>Unusual structural features revealed by the solution NMR structure of the NLRC5 caspase recruitment domain.</article-title>
<source>Biochemistry</source>
<year>2014</year>; 
<volume>53</volume>: <fpage>3106</fpage>&#x02013;<lpage>3117</lpage>.<pub-id pub-id-type="pmid">24815518</pub-id></mixed-citation></ref><ref id="bibr30-0300060520925352"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downs</surname><given-names>I</given-names></name><name><surname>Vijayan</surname><given-names>S</given-names></name><name><surname>Sidiq</surname><given-names>T</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>CITA/NLRC5: a critical transcriptional regulator of MHC class I gene expression.</article-title>
<source>Biofactors</source>
<year>2016</year>; 
<volume>42</volume>: <fpage>349</fpage>&#x02013;<lpage>357</lpage>.<pub-id pub-id-type="pmid">27087581</pub-id></mixed-citation></ref><ref id="bibr31-0300060520925352"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshihama</surname><given-names>S</given-names></name><name><surname>Roszik</surname><given-names>J</given-names></name><name><surname>Downs</surname><given-names>I</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>NLRC5/MHC class I transactivator is a target for immune evasion in cancer.</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2016</year>; 
<volume>113</volume>: <fpage>5999</fpage>&#x02013;<lpage>6004</lpage>.<pub-id pub-id-type="pmid">27162338</pub-id></mixed-citation></ref><ref id="bibr32-0300060520925352"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Bode</surname><given-names>AM</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>AKT as a therapeutic target for cancer.</article-title>
<source>Cancer Res</source>
<year>2019</year>; 
<volume>79</volume>: <fpage>1019</fpage>&#x02013;<lpage>1031</lpage>.<pub-id pub-id-type="pmid">30808672</pub-id></mixed-citation></ref><ref id="bibr33-0300060520925352"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roncolato</surname><given-names>F</given-names></name><name><surname>Lindemann</surname><given-names>K</given-names></name><name><surname>Willson</surname><given-names>ML</given-names></name></person-group>, <etal>et&#x000a0;al</etal>
<article-title>PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2019</year>; 
<volume>10</volume>: <fpage>D12160</fpage>.</mixed-citation></ref></ref-list></back></article>